Key Takeaways:
- Earnings Momentum: Johnson & Johnson posted $25 quarterly revenue and $6 profit, confirming durable demand across pharma and MedTech portfolios.
- Margin Profile: Operating margins near 34% reflect pricing discipline and scale efficiency, supporting steady earnings despite $500 tariff headwinds.
- Price Target: Based on current assumptions, JNJ stock could reach $277 by 2028 as pipeline growth offsets legal and pricing pressures.
- Return Outlook: This implies a 26% total return from $220, translating to about 8% annualized returns over 3 years.
Johnson & Johnson (JNJ) operates global pharmaceutical and medical device businesses, with scale across Innovative Medicine and MedTech supporting diversified healthcare revenue streams.
Just last week, JNJ guided 2026 sales above expectations despite $500 tariffs and U.S. drug pricing pressure.
Talc litigation headlines briefly pressured shares after court testimony approval despite no change to underlying business fundamentals.
Johnson & Johnson stock posted $25 billion quarterly revenue and $6 billion profit, reflecting resilient pharma and MedTech demand.
Operating margins near 28% highlight cost control and mix strength, while a market capitalization above $500 billion reflects defensive positioning.
Management expects growth from late-stage pharma launches and MedTech recovery, with profit tied to execution and pricing discipline.
Even with improving cash flow and an $11 earnings outlook, the stock trades near 18x earnings, keeping valuation and execution closely linked.
What the Model Says for JNJ Stock
We evaluated Johnson & Johnson stock using stable healthcare demand, strong cash generation, and disciplined capital returns supporting defensive positioning.
Using 5.8% revenue growth, 34.4% operating margins, and an 18.4x exit multiple, the model projects shares reaching $276.91.
That implies a 25.8% total return, or roughly 8.1% annualized, over the next 2.9 years from current levels.
Our Valuation Assumptions
TIKR’s Valuation Model lets you plug in your own assumptions for a company’s revenue growth, operating margins, and P/E multiple, and calculates the stock’s expected returns.
Here’s what we used for JNJ stock:
1. Revenue Growth: 5.8%
Johnson & Johnson stock’s revenue grew 6.0% over the last year, outpacing its 2.7% five-year average, supported by Innovative Medicine momentum and stabilizing MedTech volumes.
Recent quarters showed $24.6 billion in Q4 revenue, reflecting resilient prescription demand despite pricing pressure and litigation noise affecting near-term sentiment.
Growth visibility improves as Stelara headwinds ease and late-stage oncology and immunology assets scale, partially offset by slower device recovery in China.
According to consensus analyst estimates, a 5.8% revenue growth assumption balances diversified demand strength against mature scale and regulatory constraints.
2. Operating Margins: 34.4%
Johnson & Johnson stock has sustained operating margins near 30% historically, reflecting high-margin pharmaceuticals and disciplined cost structures across its global platform.
Recent operating margins around 27% show temporary pressure from tariffs, litigation costs, and heavier investment cadence early in 2026.
Margin normalization is supported by mix shift toward Innovative Medicine, easing cost inflation, and operating leverage as MedTech utilization recovers.
In line with analyst consensus projections, operating margins of 34.4% reflect normalization toward historical peaks without assuming extraordinary cost reductions.
3. Exit P/E Multiple: 18.4x
Johnson & Johnson has historically traded between roughly 16× and 18× earnings, consistent with its defensive growth profile and dividend-supported shareholder base.
Current valuation reflects investor caution around talc litigation, even as earnings guidance and cash flow expectations improve into 2026.
Sustaining an 18.4× multiple requires steady execution, litigation containment, and confidence in pipeline durability rather than accelerating growth narratives.
Based on street consensus estimates, an 18.4× exit multiple aligns stable earnings visibility with modest valuation normalization as legal uncertainty recedes.
What Happens If Things Go Better or Worse?
Johnson & Johnson’s outcomes depend on drug pipeline execution, MedTech recovery, and litigation management, setting up distinct operating paths through 2030.
- Low Case: If pricing pressure persists and devices lag, revenue grows 5.2% with margins near 29.0% → 1.8% annualized return.
- Mid Case: With core pharmaceuticals steady and MedTech stabilizing, revenue grows 5.8% and margins reach 30.9% → 6.1% annualized return.
- High Case: If pipeline launches exceed expectations and cost discipline holds, revenue reaches 6.3% with margins near 32.4% → 9.9% annualized return.
How Much Upside Does It Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
